L
Lumiata
Health Tech & Medtech · San Mateo, United States · Founded 2013
Predictive analytics to provide better health care MoreLess
Lumiata operates in the healthcare analytics sector, leveraging artificial intelligence to predict costs and manage risks for healthcare providers and insurers. The company utilizes a vast repository of over 100 million patient records, 35 thousand physician curation hours, and 50 million articles mined from PubMed to generate deep insights. Lumiata's core products include AI models for predicting high-cost healthcare claims, disease onset, and group costs. The platform serves data scientists, healthcare professionals, and HR managers by providing tools for data preparation, cleansing, and model building. Lumiata's business model revolves around offering subscription-based access to its AI-powered analytics platform, enabling clients to make informed decisions and drive better outcomes. The company generates revenue through these subscriptions and additional services such as data enrichment and customization of AI models.
Keywords: AI healthcare analytics, cost prediction, risk management, patient data, disease onset, telemedicine, data preparation, clinical insights, predictive models, healthcare providers.
Company overview
Lumiata company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2013
- Headquarters
- San Mateo, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 61.6
Valuation & funding
Lumiata funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Apr 2022 | $0 | — | Somatus | ↗ |
| SERIES B✓Equity / VC | Jan 2021 | $14M | $56M | Khosla Ventures · Blue Venture Fund · Defy Partners · AllegisCyber Capital | — |
| SERIES B✓Equity / VC | Jul 2018 | $11M | $44M | Intel Capital · BlueCross BlueShield Venture Partners · Sandbox Industries · Khosla Ventures | ↗ |
| SEED✓Equity / VC | Nov 2017 | — | — | Castor Ventures · Alumni Ventures | — |
| SERIES B✓Equity / VC | May 2016 | $10M | $40M | Khosla Ventures · Sandbox Industries · Blue Cross and Blue Shield Association · Intel Capital | — |
| SERIES A✓Equity / VC | Sep 2014 | Sandbox Industries · BlueCross BlueShield Venture Partners | — | ||
| SERIES A✓Equity / VC | Jan 2014 | Khosla Ventures | — | ||
| EARLY VC✓Equity / VC | Jul 2013 | Khosla Ventures | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 3 |
| 2025 | 40 |
| 2024 | 40 |
| 2023 | 40 |
| 2022 | 40 |
| 2021 | 40 |
| 2020 | 37 |
Growth signals
Lumiata website traffic
Latest recorded traffic for Lumiata is 90 monthly website visits, down 93.6% over the last three months. Lumiata's team declined 92.5% over the past year.
Comparisons
Lumiata compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Lumiata's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Lumiata has talent and traffic
team presence
In the news
Latest news about Lumiata
Recent press, funding announcements, and product moves mentioning Lumiata — open to read from the original sources.
Market sentiment
What the market is saying about Lumiata
An AI-synthesized read of the highest-engagement posts about Lumiata on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lumiata’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.





















